Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 20/20 | 0.42 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.41 |
| ▸ | CALCA | P06881 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12206967 | 0.96 | CALCRL (0.43) | CALCRLRAMP1CALCA | |
| SCHEMBL13740258 | 0.92 | CALCRL (0.44) | CALCRL | |
| SCHEMBL13740257 | 0.92 | CALCRL (0.44) | CALCRL | |
| SCHEMBL1673182 | 0.88 | CALCRL (0.45) | CALCRL | |
| SCHEMBL1673176 | 0.88 | CALCRL (0.45) | CALCRL | |
| SCHEMBL13832606 | 0.85 | CALCRL (0.41) | CALCRLRAMP1CALCA | |
| SCHEMBL2520422 | 0.85 | CALCRL (0.44) | CALCRLRAMP1CALCA | |
| SCHEMBL829061 | 0.85 | CALCRL (0.51) | CALCRLRAMP1CALCA | |
| SCHEMBL828554 | 0.85 | CALCRL (0.51) | CALCRLRAMP1CALCA | |
| SCHEMBL14865855 | 0.82 | CALCRL (0.62) | CALCRLRAMP1CALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2697228-B1 | CGRP RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-07-27 | — | — | EP | disclosed |
| US-8748429-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748429-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130096130-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2013-04-18 | — | — | US | disclosed |
| US-20130096130-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2013-04-18 | — | — | US | disclosed |
| WO-2012154354-A1 | CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096130-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | CALCRL 1/4885RAMP1 130/4885CALCA 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.